In patients with metastatic castration-resistant prostate cancer, early genetic testing may help personalize treatments in the first-line as a study suggests
According to the findings of the CAPTURE study, recently published in Annals of Oncology, men with metastatic castration-resistant prostate cancer (mCRPC) harboring alterations in BRCA1 and BRCA2 genes derive limited benefit from first-line standard treatments including taxanes and androgen receptor signaling inhibitors compared to those with homologous recombination repair (HRR) mutations other than BRCA1/2 or no HRR mutations (Ann Oncol. 2024 Feb 10:S0923-7534(24)00043-7).